-
Mashup Score: 4Cabozantinib and Nivolumab Combination Therapy Shows Durable Efficacy in Advanced Kidney Cancer - María Bourlon - 2 month(s) ago
Pedro Barata and María Bourlon discuss the CheckMate 9ER trial’s 55-month follow-up, revealing the enduring benefits of cabozantinib plus nivolumab over sunitinib in untreated advanced renal cell carcinoma. The trial highlights significant advancements in overall survival, progression-free survival, and response rates, alongside improved quality of life for patients. Dr. Bourlon emphasizes the…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
Cabozantinib and nivolumab combination therapy show durable efficacy in advanced #KidneyCancer. María Bourlon, MD, MSc joins @PBarataMD @caseccc to discuss #CheckMate9ER 55-month follow-up, revealing the enduring benefits of cabo + nivo over sunitinib > https://t.co/LGHMGkjsOo https://t.co/lRDatnvYxz